This medicine is authorised for use in the European Union.


Jylamvo is an anti-inflammatory and cancer medicine used to treat the following conditions: 

  • active rheumatoid arthritis (a disease causing inflammation in joints) in adults;
  • severe juvenile idiopathic arthritis (inflammation of joints in children) in patients from 3 years of age when NSAIDs (non-steroidal anti-inflammatory drugs) have not worked well enough;
  • severe disabling psoriasis (an inflammatory disease causing red, scaly patches on the skin) in adults when other treatments have not worked well enough;
  • severe psoriatic arthritis (inflammation of joints that occurs in patients with psoriasis) in adults;
  • acute lymphoblastic leukaemia (ALL), a cancer of white blood cells, in adults and children over the age of 3

Jylamvo contains the active substance methotrexate. 

Jylamvo is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Jylamvo is given in a different way. The reference medicine for Jylamvo is Methotrexat Lederle injection.

This EPAR was last updated on 31/10/2019

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Arthritis, Psoriatic
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Psoriasis
  • Arthritis, Rheumatoid
  • Arthritis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Therakind (Europe) Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

3 Inn's Quay
Dublin 7
D07 PW4F

Product information

21/10/2019 Jylamvo - EMEA/H/C/003756 - A31/0002


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

In rheumatological and dermatological diseases

  • Active rheumatoid arthritis in adult patients.
  • Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.
  • Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.

In oncology

  • Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating